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Abstract & Keywords 
 
Background 
 
The carotid artery is a novel access route for transcatheter aortic valve implantation 
(TAVI). This may represent a viable alternative in patients unsuitable for TAVI via 
traditional transfemoral access, up to 20%, as well as other access routes such as 
subclavian, transapical and aortic. This systematic review summarises the current 
evidence for its safety and feasibility. 
 
Methods 
 
A systematic review was conducted as per the Preferred Reporting Instructions for 
Systematic Reviews and Meta-analysis (PRISMA) guidelines using five electronic 
databases.  
 
Results 
 
16 studies were identified, including three prospective cohort studies, one 
retrospective cohort study, three case series and eight case reports. Data on 74 patients 
(mean age 76.9 years) was extracted including pre-operative work-up, technical 
procedure details and outcomes.  
 
This found 1 intraoperative death, 2 further deaths within 30 days, two incidences of 
transient ischaemic attack, no incidences of stroke, myocardial infarction, carotid 
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access site complications or infection, 1 patient required new dialysis and 1 patient 
had an intraoperative dissection which resolved. Follow-up from 30 days to 1 year 
showed symptomatic improvement and echocardiographic improvement in line with 
those seen in transfemoral TAVI.  
 
Conclusions 
 
The available data on TAVI via carotid access demonstrate technical feasibility with 
comparable outcomes to other traditional access routes.  A low number of patients, 
heterogeneous clinical endpoints and relatively short follow-up periods limit formal 
meta-analysis and firmer conclusions. For patients in which other access routes are 
impossible, TAVI via carotid access represents a viable and potentially crucial 
alternative in patients who might otherwise be untreatable. 
 
Keywords: Transcatheter aortic valve, TAVI, carotid 
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1. Introduction 
 
Patients with severe symptomatic aortic stenosis or regurgitation were classically 
managed with a valve replacement during open surgery. In the last 15 years, since the 
first description in 2002 (1), transcatheter aortic valve implantation (TAVI) is a viable 
alternative for those patients with multiple comorbidities considered at high risk for 
open surgery (2).  
 
Transfemoral access is the most widely used access route for TAVI, is the least 
invasive and now also allows for a complete percutaneous procedure (3-5). However, 
approximately 20% of patients approved for TAVI are not suitable for transfemoral 
access (6). There are relative and absolute contraindications to the use of this access 
route such as iliofemoral arteriopathy, tortuosity, severe calcification, abdominal 
aortic aneurysm or previous vascular surgery. Alternative access routes to the aortic 
valve include transapical, transaortic and subclavian/axillary access.  
 
The transapical approach is currently the second choice access route in many 
institutions (7). However, the need for a left anterior minithoracotomy and a left 
ventricular apical puncture makes this is a far more invasive procedure. This is often 
still not suitable for patients with some significant comorbidities, which also exclude 
them from open surgery such as severe respiratory disease or left ventricular 
dysfunction.  
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The transaortic approach offers similar drawbacks through the need for a general 
anaesthetic and an upper ministernotomy (8). It can be challenging from a surgical 
perspective in patients who have undergone a previous coronary artery bypass graft 
(CABG) with patent venous grafts. It is likewise unsuitable in patients with severe 
respiratory disease and those with a „porcelain aorta‟. 
 
Subclavian (or transaxillary) access has been shown to be a safe approach but can also 
be precluded by previous CABG as with the transaortic approach and also by size of 
the artery and calcification at the aortic arch (9).  
 
In 2010 Modine and colleagues published the first case report on TAVI via a carotid 
access route offering a further alternative (10). The purpose of this systematic review 
is to summarise the current evidence available on TAVI via carotid access and assess 
its feasibility and safety as an alternative access route.  
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2. Methods 
 
The review was conducted according to the Preferred Reporting Items for Systematic 
Reviews and Meta-Analysis (PRISMA) checklist for systematic reviews (11).  
 
2.1 Literature Search 
Medline (via PubMed), OvidSP, Embase, Google Scholar and Cochrane databases 
were searched to identify all reports describing TAVI via carotid access. The 
following „Medical Subject Headings‟ (MeSH) search terms were used: “TAVI”, 
“TAVR”, “PAVR”, “aortic valve replacement”, “aortic valve implantation”, “aortic 
valve insertion”, “aortic heart valve replacement”, “aortic heart valve implantation”, 
“aortic heart valve insertion”.  
 
The „related articles‟ function was used to broaden the search. Based on the title and 
abstract, cases were sought in which carotid access was used to perform a TAVI. 
References of the articles selected were also searched manually. No language 
restrictions were used. Articles published before 1st January 2002 were excluded as 
TAVI via any route was not performed before this time. The latest date for this search 
was 29
th
 March 2016 (the full search strategy can be obtained from TS on request).  
 
2.2 Inclusion Criteria for Review 
Any article was included that used either of the common carotid arteries as the 
primary access vessel for aortic valve replacement.  
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2.3 Exclusion Criteria for Review 
Studies published prior to 2002 were excluded.  
 
2.4 Data Extraction and Validation of Studies 
Three reviewers (TS, MH, AC) independently extracted the following data from each 
study: first author, year of publication, number of patients in study, mean age of 
patients, sex of patients, co-morbidities, pathology being treated, co-morbidities, 
contraindications to open surgical repair, contraindications to TAVI via a 
transfemoral, transapical, transaortic or subclavian approach, approach taken and 
reason for this, pre-operative work-up, carotid assessment, anaesthetic, equipment 
used, cerebral monitoring used, qualitative statements on procedure, valve assessment 
post-procedure, paravalvular regurgitation, mortality, complications, follow-up and 
outcome at follow-up. Data were also retrieved on the following outcomes of interest: 
valve assessment post-operatively, paravalvular regurgitation, mortality, neurological 
complications, vascular access site complications, other complications according to 
the Valve Academic Research Consortium (VARC-2) criteria (12), follow-up and 
outcome at follow-up.  
 
2.5 Data Analysis 
The outcome measures were mortality, immediate complications, valve function and 
follow-up of patients. Data regarding valve function were sometimes unavailable 
whilst those involving follow-up involved dissimilar time spans between reports and 
was also sometimes unavailable. Overall the data were heterogeneous and formal 
meta-analysis could not be performed on any extracted data.  
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3. Results 
 
3.1 Systematic Search Strategy 
 
The systematic search of the databases revealed 712 publications for possible 
inclusion. Following the removal of duplicates and publications from before 2002, the 
remaining titles and abstracts were reviewed and irrelevant publications were 
excluded. This left 36 publications, which were reviewed in their entirety. Of these, 
21 were excluded on more detailed inspection of the full text. No additional articles 
were added from manual review of the references. A total of 16 papers or abstracts 
were scrutinised and data extracted. The 16 reports comprised three prospective 
cohort studies, one retrospective cohort study, four case series and eight case reports. 
Three of the case series had sufficient detail for the data to be extracted as individual 
cases (6, 13, 14). One group, Azmoun et al., presented or published the same content 
with increasing patients in their series (15). We selected the published article for data 
extraction as it provided the most detail on patient characteristics and outcomes. One 
case series was presented as an oral presentation (16). The search strategy is shown in 
Figure 1 and is based upon the PRISMA flow diagram for systematic review (11) 
 
3.2 Patient Demographics, Comorbidities and Contraindications to Open or Other 
TAVI Access options 
 
In the 16 reports, 74 patients underwent TAVI via carotid access. The mean patient 
age was 76.9 years (range 27-91 years), with 59.5% of patients being male (ratio M 
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44:30 F). 69 procedures were performed for severe aortic stenosis, whilst five were 
performed for aortic regurgitation. One report was in a failed aortic bioprosthesis 
(17).  
 
All patients were considered unfit for an open procedure. Transfemoral access was 
contraindicated due to vessel disease, calcification, tortuosity, significant risk of 
rupture and risk of distal emboli. The transapical approach was contraindicated 
chiefly due to severe pulmonary disease or previous coronary artery bypass graft 
(CABG). Finally the subclavian route was mostly precluded due to difficult anatomy 
such as angulation, stenosis and calcification; or again from previous CABG.  
 
A summary of baseline patient characteristics, comorbidities, risk stratification scores 
and reasons for avoidance of other traditional endovascular techniques is presented in 
Table 1 and Table 2.  
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Figure 1. PRISMA Flowchart 
 
 
 
 
Records identified 
through database 
searching  
(n=712) 
 
 
 
Records screened 
(n=532) 
Full-text articles 
assessed for eligibility 
(n=37) 
Studies included in 
qualitative synthesis 
(n=16) 
Published before 
2002 (n=113) 
Excluded by Title and 
Abstract  
(n=382) 
Full-text articles 
excluded (n=21) 
 
·Opinion/review 
article (n=4) 
·Non-carotid access 
used (n=8) 
·No specific 
extractable data from 
large studies (n=3) 
·Duplicate content 
(n=2) 
·Animal studies (n=4) 
 
 
Duplicates removed 
(n=180) 
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Table 1. Baseline Characteristics  
 
First 
author; 
Year  
Design Specific study interest Exclusion 
Criteria 
No. 
patients 
Age (years) M:F Pathology Co-morbidities Euroscore / STS 
Huczek 
2015 
Case series 
(Case 1) 
- - 1 74 F AS. 
Mean gradient 37 mmHg, valve area 0.45cm2, LV EF 
60%. 
CABG, ascending aortoplasty, previous AVR with bioprosthesis, NYHA Class III, AAA, thoracic aortic aneurysm, HTN, 
CKD, hypothyroidism, right masterctomy, GI bleed, early stage colorectal CA 
STS 4.3% 
Huczek 
2015 
Case series 
(Case 2) 
- - 1 84 M AS. 
Mean gradient 47mmHg, peak gradient 86mmHg, jet 
velocity 4.5m/s, valve area 0. 8cm2, 
CABG (LIMA to LAD), porcelain aorta, HF NYHA Class III STS 8.8% 
Daly 2015 CR Previous mitral valve 
replacement 
- 1 80 F AS.  Rheumatic heart disease, MVR, AF, CKD (eGFR 49mL/min), severe COPD (FEV1 46% predicted). Logistic Euroscore 
42.6%, STS 17.6% 
Huber 
2015 
Case series 
(Case 1) 
AR due to degenerated 
stentless Shelhigh 
conduits (Aortic root 
replacement) 
- 1 84 M AR.  
LV dilatation (55mm). Severely reduced LV EF.  
Previous ascending aortic aneurysm (52mm) managed with elective composite valve-graft conduit replacement of 
the aortic root, replantation composite valve-graft conduit replacement of the aortic root, replantation of the 
coronary arteries and bypass of the right coronary artery. CKD on haemodialysis. HF NYHA III.   
Euroscore II 14%, 
STS 8.5% 
Huber 
2015 
Case series 
(Case 2) 
AR due to degenerated 
stentless Shelhigh 
conduits (Aortic root 
replacement) 
- 1 74 M AR.  
Aneurysm of 54mm at distal anastomosis of composite-
graft and native aorta.  
Previous acute type aortic dissection. Replacement of aortic valve and ascending aorta with stentless Shelhigh valved 
conduit. Multiple ischaemic strokes due to transient cerebral hypo-perfusion following this. Frailty (BMI 19.6 kg/m2). 
HF NYHA IV.  
Euroscore II 3.6%, 
STS 3.9% 
Huber 
2015 
Case series 
(Case 3) 
AR due to degenerated 
stentless Shelhigh 
conduits (Aortic root 
replacement) 
- 1 56 M AR.  
LV EF 30%.  
ADPKD, unilateral left renal agenesis. Previous Type A aortic dissection managed with emergency aortic valve 
replacement with graft conduit. Subacute infective endocarditis with Strep. bovis 3 years later, followed by abscess 
formation around the mechanical valve requiring replacement of aortic valve and ascending aorta with stentless 
Shelhigh valved conduit. Chronic renal failure requiring haemodialysis via fistula. Pacemaker for LV EF 30% with 
LBBB. HF NYHA Class IV.  
Euroscore II 16%, 
STS 9.4% 
Pozzi 2015 Prospective 
cohort study 
Previous ipsilateral carotid 
endarterectomy 
Carotid 
diameter < 
6.5mm 
9 84.6 +/- 3.6 
(range 79-
91) 
4 M:F 5 AS.  
Mean gradient 51.5 ± 11.5 mmHg, valve area 0.40 ± 
0.09cm2, , mean jet velocity 4.7 ± 1.1 m/s.  
HTN 9 (100%), DM 1 (11.1%), hypercholesterolemia 6 (66.5%), COPD 1 (11.1%), frailty 2 (22.2%), previous CABG 2 
(22.2%), CKD 5 (55.5%), previous CVA/TIA 4 (44.5%), AF 4 (44.5). 
Euroscore II 7.96 ± 
6.51%, STS 7.01 ± 
9.62 % 
Thourani 
2015 
Retrospective 
cohort study 
Retrospective cohort of 
469 patients who 
underwent TAVI via 
alternative access routes 
Carotid 
diameter 
<8mm or 
evidence of 
stenosis 
11 68.9 +/- 
23.6 
5 M:F 6  AS.  
Mean gradient 42.0 ± 18.1 mmHg, valve area 0.62cm2 ± 
0.17, jet velocity 4.3 ± 0.6m/s, LV EF 45.5 ± 17.4%  
Cerebrovascular disease 3 (27.3%), DM 4 (36.4%), mod-severe COPD 6 (54.6%), dyslipidaemia 9 (81.8%), HTN 9 
(81.8%), history of infective endocarditis 1 (9.1%), immunosuppression 1 (9.1%), CKD 5 (45.5%) (none on dialysis), 
peripheral vascular disease 8 (72.7%), previous CVA 1 (9.1%), previous CABG 6 (54.6%), previous valve procedure 9 
(81.8%), Heart failure NYHA 3 or 4 in 10 (90.9%), previous MI 2 (18.2%).  THESE ARE THE SAME CONFIRM. 
STS 17.1% ± 8.8% 
Benhalla 
2015 
CR Via prosthesis carotid 
artery 
- 1 83 M AS.  
Severely calcified aortic bioprosthesis. Mean gradient 
53mmHg, valve area 0.8cm2, LV EF 40%. 
HF (due to severe degenerative aortic bioprosthesis), DM, HTN, COPD, peripheral artery disease, coronary artery 
disease. 
Euroscore II 36% 
Azmoun 
2014 
Prospective 
cohort study 
- Carotid 
diameter 
<6mm or 
stenosis, 
calcification 
or major 
tortuosity 
19 82.2 +/- 5.9  14 M:F 5 AS.  
Mean gradient 42.3 ± 15.9 mmHg, LV EF 49 ± 16% 
Severe peripheral vascular disease. Occlusion or severe stenosis in iliofemoral arteries in all patients. Large AAA 
(>50mm) in 1 patient (5.3%), previous abdominal aortic endoprosthesis in 2 patients (10.5%), previous 
aortobifemoral bypass in 3 (15.8%), previous axillo-bifemoral bypass in 1 (5.3%). 
Logistic EuroScore 
25.2 ± 15.7%, STS 
11.9 ± 5.1%. 
Maureira 
2014 
CR AR due to degenerate 
ascending aorta 
replacement 
- 1 68 M AR.  
LV dilatation (72mm). LV EF 52%. 
HTN, DM II, severe COPD (FEV1 <40%), previous Type A Aortic dissection, replacement of ascending aorta. Stable 
chronic aortic dissection (aortic arch extending to abdominal aorta just below right renal artery, with no innominate 
artery involvement). HF NYHA III. 
Logistic EuroScore 
11.05%, STS  
5.43% 
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Modine 
2014 
CR - - 1  85 M AS.  
Valve area 0.53cm2, mean gradient 41mmHg, max 
gradient 61mmHg, peak jet velocity 4.2m/sec, 
preserved LV EF.  
Previous stroke, subdural haematoma, bronchiectasis, AF, peripheral artery disease, laryngeal neoplasm, 
nephrectomy, CKD.  
Logistic Euroscore 
46.48%, STS 
13.4%.  
Rajagopal 
2014 
CR - - 1 81 M AS.  
Peak gradient 54 mmHg, valve area 0.6cm2, LV EF 42%. 
Previous CABG (LIMA to LAD, 2 vein grafts, shown to be patent). DM II, HTN, Stage 3 CKD, severe asthma. Euroscore II 
26.9%, STS 25.1% 
Magalhaes 
2013 
CR Combined left carotid 
endarterectomy, left 
carotid-subclavian tunnel 
bypass and transcartoid 
TAVI 
- 1 81 M AS.  
Mean gradient 56mmHg, valve area 0.57cm2, mean 
gradient 56 mmHg, LV EF 65%  
HF NYHA Class III. Episodes of presyncope. DM, HTN, dyslipidaemia, previous aortic bi-iliac and aortic-left renal 
artery bypass due to Leriche's Syndrome. Previous CABG (bypass grafts shown to be patent). Previous right carotid 
endarterectomy.  
Euroscore II 25.9% 
Khan 2013 Case series 
via oral 
presentation 
- - 7 82 1 M:F 6 AS.  
(LV EF <40% in one patient) 
Previous CABG 2 patients, previous MI 1 patient, CKD 3 patients.  Logistic EuroScore 
12.43 ± 2.87% 
Guyton 
2013 
Case series 
(case 1) 
- - 1 80 F AS. HF NYHA Class IV. Porcelain ascending aorta, calcification of both subclavian arteries, mod-severe pulmonary 
dysfunction, frail, calcification of costal cartilages and narrow rib spaces.  
Not reported 
Guyton 
2013 
Case series 
(case 2) 
- - 1 27 M AR.  Shone's complex, congenital AS, coarctation of the aorta, congenital mitral stenosis. 6 previous sternotomies (repair 
of coarctation of aorta, open mitral valvuloplasty, bileaflet mechanical aortic prostesis, ICD implantation). Ross-
Konno procedure and removal of infected aortic prosthesis. Group B streptococcal endocarditis. Further homograft 
aortic root and pulmonary bioprosthetic valved conduit. HF NYHA Class III.  
Not reported 
Guyton 
2013 
Case series 
(case 3) 
- - 1 78 M AS.  
LV EF 25% 
3 vessel coronary disease and AS. Porcelain aorta found at sternotomy bypass completed but valve not replaced. 
(Patent grafts at 1 year). Severe lung disease requiring home oxygen. Severe peripheral vascular disease. 
Not reported 
Modine 
2012 
Prospective 
cohort study 
- Carotid 
diameter 
<7.5mm 
12 85 (range 
72-88) 
8 M:F 4 AS.  
Mean gradient 51 mmHg (range 46-54mmHg), mean LV 
EF 0.60 (range 0.42-0.72mmHg).  
HF NYHA class III/IV (50%), pacemaker (16%), AAA (33%), peripheral vascular disease (91%), CKD (25%). 7 patients 
left/right internal thoracic artery bypass. 
Logistic EuroScore 
16 % (range 9-
20%), STS  6 +/- 5 
Mouillet 
2011 
CR - - 1 90 F AS.  
Valve area 0.56cm2. Mean gradient 82 mmHg. LV EF 
55%.  
HTN, severe peripheral vascular disease, hypercholesterolaemia, history of pulmonary TB. HF NYHA Class II.  Logistic EuroScore 
53.29% 
Modine 
2010 
CR First case report - 1 89 M AS.  
Peak gradient 75mmHg, valve area 0.8cm2, LV EF 50%. 
Type 1 Aortic arch, pacemaker. HF NYHA III.  Logistic EuroScore 
14.6% 
Table 1 Abbreviation List  
AS  Aortic stenosis 
AR Aortic regurgitation 
MVR Mitral valve replacement 
CKD Chronic kidney disease 
HF Heart failure 
NYHA New York Heart Association 
ADPKD Autsomal dominant polycystic kidney 
disease 
HTN Hypertension 
TIA Transient ischaemic attack 
CVA Cerebrovascular accident 
AAA Abdominal aortic aneurysm 
LV EF Left ventricle ejection fraction 
M Male 
F Female 
CR Case report 
DM Diabetes mellitus 
“-“ Indicates information not reported 
Table 1. Shows the baseline characteristics of patients involved in each of the studies. Specifically looking at the pathology 
leading to the need for intervention, and the co-morbidities of the patient groups of each study. 
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Table 2. Reason for approach selection  
 
First author; 
Year  
Stated reason open 
surgery contraindicated 
Stated reason Transfemoral TAVI contraindicated Stated reason Transapical TAVI 
contraindicated 
Stated reason subclavian 
TAVI contraindicated 
Stated reason direct aortic approach 
contraindicated 
Carotid 
approach used 
Reason for carotid side selection 
Huczek 
2015 
High risk - Previous CABG with LIMA to LAD, 
saphenous vein grafts to right coronary 
and marginal branch. 
- - L - 
Huczek 
2015 
High risk Severe atherosclerosis iliac arteries Previous CABG with LIMA to LAD - - L - 
Daly 2015 Excessive risk due to 
frailty and multiple co-
morbidities. 
Small iliofemoral arteries <6mm Severely impaired pulmonary function 
with poor pulmonary reserve, 
calcification and posterior displacement 
of the cardiac apex 
Small subclavian arteries 
<6mm 
Severely impaired pulmonary function with 
poor pulmonary reserve, calcification and 
posterior displacement of the cardiac apex 
L  - 
Huber 2015 High risk due to CKD and 
severely reduced LV EF. 
High risk of distal embolisation due to bilateral thrombosed iliac aneurysms with 
decreased lumen diameter. 
No data to support use of TA implanted 
valve in AR. 
Unfavourable angulation of 
left subclavian 
- R - 
Huber 2015 High risk due to prior 
ischaemic stroke and 
frailty. 
High risk of rupture due to aneurysm of 54mm at distal anastomosis of 
composite-graft and native aorta.  
No data to support use of TA implanted 
valve in AR. 
High risk of rupture due to 
aneurysm of 54mm at distal 
anastomosis of composite-
graft and native aorta. 
- R Favourable angulation and minimal 
atherosclerosis.  
Huber 2015 High risk due to 
advanced age and 
reduced mobility 
Chronic aortic dissection from left subclavian artery to both iliac arteries.  No data to support use of TA implanted 
valve in AR. 
Chronic aortic dissection from 
left subclavian artery to both 
iliac arteries. Right subclavian 
route restricted by presence 
of pacemaker. 
- L  - 
Pozzi 2015 - - - - - L More direct approach in the axis of the 
aortic valve and so easier introduction and 
deployment of the prosthetic valve. 
Reduced distance to aortic annulus and 
direct trajectory allows exact control of 
catheters and guide wires.  
Thourani 
2015 
Combined risk of death 
and irreversible severe 
morbidity >50%. 
Ileofemoral vessel size, tortuosity, calcification. LV EF <15% or severe COPD with FEV1 
<35% 
- Porcelain aorta or previous median 
sternotomy 
R  - 
Benhalla 
2015 
Not fit Severe peripheral vascular disease – specifically iliofemoral lesions - Calcification in innominate 
artery. Subclavian diameter 5-
6mm with calcification 
- L  - 
Azmoun 
2014 
- Occlusion or severe stenosis in iliofemoral arteries in all patients. AAA (>50mm) in 
1 patient, previous abdominal aortic endoprosthesis in 2 patients, previous 
aortobifemoral bypass in 3, previous axillo-bifemoral bypass in 1. 
Previous CABG with patent internal 
thoracic artery grafts.  
- - 8 R, 11 L Most suitable chosen based on preoperative 
contrast enhanced CT 
Maureira 
2014 
High risk pulmonary 
complications & 
prolonged ventilation  
(Severe hypoxaemia at 
rest and impaired 
spirometry). 
- Insufficient prosthesis size. Severe 
pulmonary dysfunction. 
Less easy to access and 
control in event of vascular 
complication (vs carotid 
access) 
- R - 
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Modine 
2014 
 Iliofemoral arteries unsuitable due to circumferential calcification and tortuosity.  Severe respiratory dysfunction Narrow calcified left 
subclavian artery.  
Severe respiratory dysfunction L   
Rajagopal 
2014 
Unsuitable for GA Severe calcific/stenotic atheromatous disease in lower abdominal aorta and iliac 
arteries. Minimum lumen diameter in common iliac arteries 4.6mm right, 5.5mm 
on left. 
Unsuitable for GA  Patent, dependent LIMA graft.  R Direct coaxial angle of the approach 
Magalhaes 
2013 
High risk candidate.  Calcification and severe stenosis of both iliac and femoral arteries.  Four bypass grafts including LIMA-LAD.  Four bypass grafts including 
LIMA-LAD. Unfavourable 
anatomy of innominate artery 
due to calcified stenosis and 
steep angulation. 
Four bypass grafts including LIMA-LAD.  L Unfavourable anatomy of innominate artery 
due to calcified stenosis and steep 
angulation. Prior right-sided 
endarterectomy.  
Khan 2013 Not suitable or high risk Extensive iliac and femoral vascular disease - Precluded - unspecified 
reason 
Precluded - unspecified reason R  - 
Guyton 
2013 
High risk candidate 5mm calcified iliac arteries at junction with aorta Calcification of costal cartilages and 
narrow rib interspaces 
Calcification of both 
subclavian arteries. 
Calcification of costal cartilages and 
narrow rib interspaces 
R  - 
Guyton 
2013 
High risk candidate Right external iliac occlusion. Small left common femoral artery (5-6mm)  Chronically occluded left 
subclavian artery, right 
subclavian artery diameter 
6.5mm.  
Previous sternotomy R RCCA larger diameter 
Guyton 
2013 
Porcelain aorta, previous 
bypass, severe lung 
disease, depressed EF. 
Severe peripheral artery disease in lower extremity Porcelain aorta, previous bypass, severe 
lung disease, depressed EF. 
Severe disease in subclavian 
arteries 
Porcelain aorta, previous bypass, severe 
lung disease, depressed EF. 
R  - 
Modine 
2012 
High risk candidate Extremely tortouse and stenosed.  CT angiography suggest diameter and 
patency not suitable 
Diameter and patency not 
suitable as suggested by CT 
angiography. 
- L More direct approach in axis of aortic valve. 
Convenient for procedure room. 
Mouillet 
2011 
High risk candidate Bilateral subocclusive calcifications in iliac arteries. Aortic annulus greater than 24mm.  Left subclavian narrow 
(6.2mm) and calcified. Right 
subclavian not in same access 
as ascending aorta.  
- L Straight path from LCCA to aortic annulus 
allowing easy and quick implantation.  
Modine 
2010 
High risk candidate due 
to advanced age.  
Severe tortuosity of abdominal aorta.  Not stated.  Severe tortuosity of right 
subclavian. Calcification of left 
subclavian artery. Pacemaker 
gives high risk of infective 
endocarditis.  
- L Type 1 aortic arch. 
Table 2 Abbreviation List  
CKD Chronic kidney disease 
LV EF Left ventricle ejection fraction 
GA General anaesthetic 
Table 2 shows why other approaches were not selected in each study. Furthermore it states which carotid side was 
used in each study and the reason for this if stated. 
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3.3 Procedural technique 
 
Three types of TAVI device were used in all studies found; the CoreValve porcine 
pericardial device (Medtronic, Inc., Minneapolis, Minnesota), the balloon-
expandable Edwards SAPIEN bovine pericardial device (Edwards Life Sciences, 
Irvine, California) and in one case the Evolut R valve (Medtronic, Inc., 
Minneapolis, Minnesota) . The left common carotid are was used for access in 41 
cases, with the right side used in 33. Where reported the procedure was done 
under local anaesthetic in 22 cases (41.5% of those reported), and general 
anaesthetic in 31 cases (58.4% of those reported), with no cases requiring 
conversion from local to general anaesthetic. In one case general anaesthetic was 
used for placement of the Dacron prosthesis prior to the TAVI procedure 
performed under local anaesthetic (17). Individual procedure techniques are 
detailed in Table 3.  
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Table 3. Technical notes  
First 
author; 
Year 
Reported work-up 
investigations 
 
Carotid assessment Circle of Willis 
assessment  
GA / LA In 
procedure 
cerebral 
monitoring 
CO results Valve Make 
& Size 
Sheath 
size 
Technical equipment used Pre-implant 
balloon 
valvuloplasty  
Rapid 
ventricular 
pacing  
Guidance 
techniques 
Surgical adjuncts and technical notes. Qualitative 
statements on 
procedure 
Huczek  
2015 
MSCT, carotid Doppler, 
vertebral artery Doppler 
- - GA CO + TCD CO – no 
hypoperfus
ion. TCD – 
160 HITS in 
65mins. 
14mins of 
low flow in 
left MCA. 
Evolut R 
23mm valve 
14Fr 
‘sheathles
s delivery 
system’ 
- - - TOE Straight tip guidewire, exchanged to Super 
Stiff Ampltaz guidewire. Initial 6Fr 
introducer sheath then 14Fr ‘sheathless’ 
delivery system 
Straight delivery 
route from 
access site to 
annulus level, 
excellent control 
during frame 
flaring with no 
need for 
repositioning 
Huczek 
2015 
Angio CT, carotid Doppler, 
verterbral artery Doppler 
- - GA CO + TCD CO – no 
hypoperfus
ion. TCD – 
200 HITS in 
72mins. 
9mins of 
low flow in 
left MCA 
29mm 
Medtronic 
CoreValve 
18Fr - - - TOE - - 
Daly 2015 Carotid Doppler study, 3D TTE 
and MSCT.   
Carotid diameter 
≥7.5mm. Disease free 
Patent LA - - 26mm 
Medtronic 
CoreValve 
18Fr  - Y Y Fluorscopic 
& TTE 
- - 
Huber 
2015 
Carotid Doppler, vertebral 
artery Doppler, TTE, cardiac 
catheterization, MSCT, 
cerebral MR angio. 
Carotid diameter 
>7mm.   
Patent GA - - 29mm 
Medtronic 
CoreValve 
18Fr  5Fr sheath used for femoral 
access and pigtail. 
Temporary pacemaker 
catheter in right ventricle.  
- Y Fluoroscopic 
& TOE (in 
2/3) 
- Short distance 
from puncture 
site to valve site 
gives well-
controlled 
release of 
prosthesis 
Huber 
2015 
Carotid Doppler, vertebral 
artery Doppler, TTE, cardiac 
catheterization, MSCT, 
cerebral MR angio. 
Carotid diameter 
>7mm.  
Patent GA - - 29mm 
Medtronic 
CoreValve 
18Fr  5Fr sheath used for femoral 
access and pigtail. 
Temporary pacemaker 
catheter in right ventricle. 
- Y Fluoroscopic 
& TOE (in 
2/3) 
- As above 
Huber 
2015 
Carotid Doppler, vertebral 
artery Doppler, TTE, cardiac 
catheterization, MSCT, 
cerebral MR angio. 
Carotid diameter 
>7mm.   
Patent GA - - 29mm 
Medtronic 
CoreValve 
18Fr  5Fr sheath used for femoral 
access and pigtail. 
Temporary pacemaker 
catheter in right ventricle. 
- Y Fluoroscopic 
& TOE (in 
2/3) 
- As above 
Pozzi 2015 Carotid Doppler, vertebral 
artery Doppler, TTE, 
coronary angio, CT scan. 
Carotid diameter 
≥6.5mm. 
- GA CO Not below 
55% 
Medtronic 
CoreValve 
18Fr  - - - - - - 
Thourani 
2015 
Carotid Doppler, TTE.  Carotid diameter 
>8mm. No stenosis. 
- -  CO  Edwards 
SAPIEN 
23mm (n=7), 
26mm (n=4) 
- 6Fr sheath in femoral 
artery and pigtail catheter. 
Temporary right ventricular 
pacemaker (via femoral 
Y Y Fluoroscopic 
& TTE 
Bypass shunt in distal carotid arteriotomy to 
maintain cerebral perfusion. 
- 
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vein) 
Benhalla 
2015 
TTE, TOE  Carotid diameter 
≥6.5mm. 
- GA 
for 
Dacro
n 
prost
hesis, 
then 
LA  
Electroencep
halogram 
(EEG) 
 Medtronic 
CoreValve 
- - - - Fluoroscopic  Use of 8mm prosthesis carotid in Dacron to 
facilitate procedure. (Placed under GA via 
endarterectomy and connected end to side). 
 
Azmoun 
2014 
Coronary angio, TTE, 
pulmonary function testing, 
MSCT  
Carotid diameter 
>6mm. No stenosis, 
calcification or major 
tortuosity. 
 LA Awake 
tests 
 Edward 
SAPIEN 
26mm (n=1), 
29mm (n=3), 
Medtronic 
CoreValve 
26mm (n=3), 
29mm (n=5), 
31mm (n=6) 
18Fr or 
20Fr  
5Fr femoral/radial sheath 
for angiographic 
visualisation.  
Y Y Fluoroscopic Passive antegrade carotid perfusion through 
a temporary femoro-carotid shunt. In two 
patients with loss of consciousness on cross-
clamping 
More direct 
route & shorter 
distance to valve 
enhanced sheath 
and catheter 
stability and 
improves 
movement 
precision. More 
accurate 
prosthesis 
positioning.  
Maureira 
2014 
CT angio, Transcranial 
Doppler echo 
Disease free  Patent - - - 31mm 
Medtronic 
CoreValve 
(oversized 
10%) 
- - - - Fluoroscopic  - Easier to access 
and control 
Modine 
2014 
Not reported Carotid diameter 
>7mm. No stenosis. 
(10mm between 
aortic annnulus and 
ostium of left 
coronary artery.) 
Patent GA CO  Edward 
SAPIEN 
26mm  
19Fr  - Y Y Fluoroscopic  - Found 
positioning and 
control 
considerably 
easier than 
transfemoral. 
Rajagopal 
2014 
CT angio, Carotid MRI Carotid diameter 
≥8.5mm.. (LCCA 
6.5mm with 
moderate (60%) 
stenosis). 
Patent LA CO + 
awake 
tests 
Minimum 
56% 
Medtronic 
CoreValve 
26mm 
18Fr  Temporary pacing wire via 
right femoral vein. Invasive 
arterial BP monitoring via 
radial artery. 
Y (20mm 
balloon)  
Y (180bpm) Fluorscopic  
& TTE 
- - 
Magalhaes 
2013 
Coronary angio, CT scan Carotid diameter 
≥8.3mm. High grade 
stenosis at 
bifurcation.  
Patent GA   Medtronic 
CoreValve 
26mm 
18Fr  - N - - (Left endarterectomy performed first). Graft 
tunnel bypass between left subclavian and 
LCC distal to intended sheath access site 
ensuring cerebral perfusion throughout 
procedure.  
- 
Khan 2013 - - - - - - -  - - - - - - - 
Guyton 
2013 
 -  GA CO  Edward 
SAPIEN 
23mm  
22Fr  6Fr sheath in right femoral 
artery for temporary right 
ventricular pacemaker and 
Y (20mm 
balloon) 
Y Fluoroscopic Javid shunt (arterial antegrade carotid 
perfusion with retrograde placement of 
delivery sheath and completion of TAVR 
- 
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pigtail for angiograms. through this due to CO drop in initial 
clamping) (passive antegrade carotid 
perfusion) (all 3 the same) 
Guyton 
2013 
 -  GA C0 Stable 
throughout 
Edward 
SAPIEN 
26mm  
24Fr  6Fr sheath in left femoral. 
Pigtail catheter for 
angiography. 
N (severe 
AR) 
Y Fluoroscopic Javid shunt connected to axillary artery 
Dacron graft and inserted antegrade into 
distal carotid artery.  
[2+ paravalvular regurgitation required a 
second 26mm valve to be deployed within 
the first 2mm more aortic in position.] 
- 
Guyton 
2013 
 Carotid diameter 
>8mm. Disease free. 
Moderate stenosis in 
right internal carotid.  
 GA CO Stable 
throughout 
Edward 
SAPIEN 
26mm  
24Fr  Left femoral artery pigtail 
and right ventricular 
pacing. Right groin 12Fr 
sheath for valvuloplasty 
and angiography.  
Y Y Fluoroscopic Javid shunt placed antegrade into common 
carotid, and 7Fr sheath in retrograde 
common carotid.  
- 
Modine 
2012 
Carotid Doppler, verterbral 
artery Doppler, TTE, 
iliofemoral & coronary 
angio, CT angio of 
subclavian, carotid & 
verterbral arteries. Cerebral 
MRI to access circle of Willis. 
Transcranial ECHO Doppler 
in some.  
-  GA CO - Medtronic 
CoreValve 
26mm or 
29mm 
18Fr  6Fr catheter in femoral 
artery for angiography and 
pacing wire. 
Y Y (during 
valvuloplast
y only) 
Fluoroscopic - - 
Mouillet 
2011 
Coronary angio, 
multidetector CT (MDCT), 
angio MDCT.  
Carotid diameter 
6.3mm.  
Patent - - - Medtronic 
CoreValve 
29mm 
18Fr  - Y - - - - 
Modine 
2010 
Carotid Doppler, vertebral 
artery Doppler, CT angio.  
Carotid diameter 
7mm. Disease free.  
 LA - - Medtronic 
CoreValve 
18Fr  - Y - - - Good 
implantation 
stability and ease 
of delivery. 
 
 
 
Table 3 Abbreviation List  
GA General anaesthetic 
LA Local anaesthetic 
CO Cerebral oximetry 
TTE Transthoracic echocardiogram 
TOE Transoesophageal echocardiogram 
TCD Transcranial Doppler monitoring 
HITS High intensity  signals 
MSCT Cardiac multi-slice computer tomography 
(contrast enhanced electrocardiogram gated) 
Table 3 shows the details of the operations in each study including the work-up carried out, the anaesthetic used, 
equipment required to perform the procedure and finally any qualitative reports from the authors. 
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3.4 Assessment of mortality 
There was one intraoperative death due to aortic annulus rupture during balloon 
valvuloplasty (15). There were two further deaths within 30 days, one from 
multisystem organ failure and one from haemopericardium(15, 16). The overall 
mortality across the studies was 4.1%. 
 
 
3.5 Other perioperative outcomes 
A number of perioperative outcomes was reported according to the VARC-2 
endpoint definitions (12). These were recorded over a range of follow-up 
periods from 1 month to 1 year. There were no incidences of myocardial 
infarction. There were no incidences of clinical stroke, however one study 
reported a new ischaemic lesion on diffusion weighted-MRI (6). Two transient 
ischaemic attacks were reported (10, 18). 10 patients required a transfusion of 
at least 2 units of packed red cells (8, 15, 19). One patient required new dialysis 
for acute kidney injury (19). One patient had a dissection intraoperatively which 
resolved (10). The most common complication was the need for insertion of a 
permanent pacemaker, which was required in nine cases (12.2%) (8, 15, 18, 20-
22). The reasons for each pacemaker insertion are detailed along with the 
individual outcome data for each study in Table 4.  
 
 
3.6 Echocardiographic outcomes 
All but three studies reported the incidence of postoperative paravalvular 
regurgitation - equivalent to the leak around the new valve. 16 patients (21.6% 
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of those reported) were found to have mild paravalvular regurgitation (13, 15, 
19, 22, 23), while three patients (4.1% of those reported) were found to have 
moderate paravalvular regurgitation (8, 15, 24); there was no incidence of 
severe paravalvular regurgitation.  
 
7 studies reported transvalvular mean pressure gradients at baseline and post-
operatively (6, 8, 15, 17-20). These demonstrated an adequate improvement in 
mean gradient values from a mean of 45.4mmHg to 11.8mmHg, as individually 
summarised in Figure 2.   
 
 
 
 
 
 
 
 
Figure 2 shows the improvement in the mean gradient (mmHg) across the aortic valve before and after the TAVI 
procedure. It shows a satisfactory improvement in all 6 studies that reported this data. 
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3.7 Follow-up and outcome 
There was variation across the studies in terms of follow-up timeline and 
outcomes assessed, as seen in Table 4. Follow-up varied from 30 days to one 
year and typically symptomatic improvement or echocardiographic 
improvements were reported. Nine studies reported change in NYHA score as an 
outcome, with all of these showing an improvement, with a return to NYHA Class 
1 seen in eight of these studies from a baseline of NYHA Class 3 or 4.  
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Table 4. Outcomes 
First author; 
Year 
Assessment of valve post-
procedure 
Aortic 
regurgitation 
(Paravalvular 
and 
Transvalvular) 
Hospit
al stay 
post-
op 
(days) 
Follow-up Mortality Neurological 
complications 
Required pacemaker TAVI-related complications according to VARC-2 Result at Follow-up 
Huczek 
2015 
Mean valve area 1.1cm2, 
mean gradient 21mmHg. 
No 7 - No No. DW-MRI post-op 
showed no pathological 
changes 
No No Improved functional status – NYHA 1 
Huczek 
2015 
Mean valve area 1.6cm2 Trivial PVR 6 - No No clinical neurology. 
DW-MRI day 3 post-op 
showed small new 
ischaemic lesion in right 
frontal lobe 
No No Improved functional status – NYHA 1 
Daly 2015 No residual gradient or aortic 
regurge. Normal MVR 
function. Normal function 
TAVI. Mean valve area 
1.8cm2, mean gradient 12 
mmHg, jet velocity 2.0m/s. 
Optimally positioned. 
Trivial PVR 7  Cardiac gated CT 30 
days post op. Clinical 
and ECHO follow up 1 
year post op. 
None at 1 year f/u  New pacemaker implanted for 
slow AF and new intermitted 
LBBB 
 Improved function status - NYHA 1.  
Huber 2015 Mean valve area 1.8cm2, 
mean gradient 6 mmHg. 
Mild PVR at 30 
day f/u 
- Echo 30 days + 6 
months 
None at 6 month f/u No No None at 6 month follow-up NYHA I.  
Doppler US of the access vessel at 6 months showed no 
normal flow patterns with no stenosis or vascular lesion. 
Huber 2015 Mean valve area 2.2cm2, 
mean gradient 3 mmHg 
Mild PVR at 30 
day f/u 
- Echo 30 days + 
Doppler US 6 months 
None at 6 month f/u No No None at 6 month follow-up Normal LV EF at 6 months.  
Huber 2015 Mean valve area 1.8cm2, 
mean gradient 6 mmHg. 
Mild PVR at 30 
day f/u 
- Echo 30 days + 
Doppler US 6 months 
None at 6 month f/u No No None at 6 month follow-up NYHA I.  
Doppler US of the access vessel at 6 months showed no 
normal flow patterns with no stenosis or vascular lesion. 
Pozzi 2015 Good valve function in all pts. 
Mean gradient 8.8 ± 3.1 
mmHg, mean aortic jet 
velocity 2.06 ± 0.34m/s 
1 pt with 
residual PVR 
n≥2 
Mean 
9 +/- 
3.3 
(Range 
6-15)  
TTE within 24 hours, 
1 week, 4 weeks.  
None at 30 day f/u  Spatial-temporal 
disorientation with 
confusion and agitation 
- cerebral CT showed 
not sign of stroke.  
2 (22.2%) permanent 
pacemaker insertion due to 
third-degree AV block 
3 pts required 2 units of packed red blood cells (already Hb 
<13 pre-procedure). 1 left groin haematoma (from temporary 
pacing lead insertion). 1 pt required post deployment balloon 
dilatation. No other TAVI-related complication. 
- 
Thourani 
2015 
Mean valve area 1.52 ± 
0.35cm2, mean gradient 11.7 
± 4.0mmHg, peak gradient 
22.9 ± 8.6mmHg, jet velocity 
2.3 ± 0.5 m/s 
PVR trace n=9 
(81.8%), mild 
n=2 (18.2%). 
Mean 
11 +/- 
9.2 
ECHO & clinic at 30 
days 
None at 30 day f/u No No 1 pt required new dialysis. 6 pts (54.6%) required transfusion 
of packed red blood cells (1.09 units +/- 1.14). 2 (18.2%) pts 
required platelet transfusion. 
 
- 
Benhalla 
2015 
Mean valve area 1.1cm2, 
mean gradient 20mmHg 
- -  No No No No Improved dyspnoea at 1 week & 1 month 
Azmoun 
2014 
Mean gradient 8 ± 4mmHg  No PVR n=8 
(44.4%), mild 
n=9 (50.0%), 
moderate n=1 
(5.3%).  
Mean 
4.6 +/- 
2.3  
TTE within 24 hours, 
before discharge and 
at 1 month.  
30 day mortality 2 
deaths (10.5%). 1 
intraoperative death by 
annulus rupture during 
preimplant balloon 
valvuloplasty. 1 in 
Loss of consciousness 
on cross clamping in 2 
pts (resolved with 
passive antegrade 
carotid perfusion) 
3 pts required permanent 
pacemaker insertion for third-
degree atrioventricular block 
4 pts required transfusion 2 units packed red cells (all with 
baseline Hb <10). No other TAVI-related complications.  
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hospital death due to 
multisystem organ 
failure (Post op day 6 in 
83 year old with poor 
preoperative condition 
Euroscore 32,STS 15.6, 
EF 25%).  
Maureira 
2014 
Mean gradient 15 mmHg, LV 
EDD 65mm, LV EF no change. 
No PVR, No AR 4  TTE at 6 months No No No No Improved exercise tolerance 
Modine 
2014 
Mean gradient 5mmHg, jet 
velocity 1.6m/s, normal LV EF.  
No AR 7  Carotid Doppler at 7 
days. ECHO & clinic 
at 1 year.  
No  Permanent pacemaker 
insertion due to LBBB and 1st 
degree heart block 
 Improved dyspnoea - NYHA II at 1 year.  
Normal carotid Doppler at 7 days & 1 year. 
Rajagopal 
2014 - 
Mild PVR   No No  No  
Magalhaes 
2013 
- Mild PVR 8 3 month clinic F/U No No Permanent pacemaker 
insertion due to new onset 
LBBB and temporary 
complete heart block 
- Improved dyspnoea - NYHA I. No further presyncope 
Khan 2013     No peri-procedural 
death. 1 death Day 20 
post discharge related 
to haemopericardium 
related to valve 
implantation.  
No peri-procedural None   
Guyton 2013 - - 6 - No No - - Symptomatic improvement at discharge. 
Guyton 2013 - - 5  - No No - - - 
Guyton 2013 - - 9  - No No - - - 
Modine 
2012 
Mean gradient 8 mmHg 
(range 4-12mmHg) 
Trivial PVR  
n=12 (100%) at 
30 day f/u 
 TTE within 24 hours,1  
week and 4 weeks.  
No 1 pt had a contralateral 
TIA 
1 pt required permanent 
pacemaker insertion due to 
severe bradycardia (2 days 
post-op) 
No - 
Mouillet 
2011 - 
Grade 1 
(moderate) AR.  
4 6 months No No No No Good clinical condition. Improved dyspnoea - NYHA I.  
Modine 
2010 
- No AR  1 month No Transient right 
hemiparesis.  CT 
showed no ischaemic or 
haemmorhagic stroke.  
No Intraoperative dissection (a partial noncircumferential 
retrograde dissection of the 
left carotid artery and ascending aorta on guide wire 
insertion). CT angio and doppler showed complete resolution 
Improved dyspnoea - NYHA II.  
Table 4 Abbreviation List  
PVR Paravalvular regurgitation 
MVR Mitral valve regurgitation 
TAVI Transaortic valve implantation 
LV EF Left ventricle ejection fraction 
TIA Transient ischaemic attack 
LBBB Left bundle branch block 
AV Atrioventricular 
NYHA New York Heart Association 
DW-MRI Diffusion-weighted MRI 
pt patient 
pts patients 
f/u Follow-up 
Table 4 shows the outcomes reported by each study both in terms of assessment of the new valve but also 
complications post-operatively and the patients welfare at follow-up.  
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4. Discussion 
 
This systematic review has looked to summarise the current evidence base for 
carotid access TAVI with a view to assessing its safety and feasibility as an 
alternative access route. The primary considerations are complications that 
relate directly to the access route – mortality, neurological complications and 
vascular access complications. The secondary aim is to show non-inferiority with 
regard to prosthetic valve placement in terms of outcomes related to valve 
replacement.  
 
 
4.1 Mortality 
The overall mortality for the patients included in the review was low – one 
intraoperative death and a further two within 30 days. This mortality rate of 
4.1% compares favourably with those reported for the transfemoral and 
transapical approach in a large meta-analysis by Li and colleagues (7.5% and 
11.3% respectively) (25). 
 
This mortality rate is particularly notable considering that carotid access, in 
many institutions, is seen as a last resort for patients unsuitable for other access 
techniques. The chief reasons for selection of carotid access over other 
techniques in this review were peripheral vascular disease, unsuitable anatomy, 
poor pulmonary reserve and prior coronary bypass using the internal mammary 
artery. 
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4.2 Neurological complications 
Two transient ischaemic attacks were reported but there were no permanent 
strokes (2.8%). The large meta-analysis by Li and colleagues showed stroke 
rates at 30-day follow-up to be 3.8% in transfemoral and 4.0% in transapical 
access routes respectively (25). This suggests the stroke risk for carotid access is 
comparable to other TAVI access routes. Azmoun and colleagues have even 
suggested that stroke risk may be lower as the aortic arch is not instrumented 
and one of the carotid arteries is clamped during the procedure (15). 
 
There was no consensus on the use of neurological monitoring. Cerebral 
oximetry was the most commonly used – in six studies (8, 14, 18-20, 23). 
Azmoun and colleagues preferred awake testing over CO monitoring as the 
physician can monitor the patients’ neurological status allowing rapid detection 
of changes (15). It also allowed for a ‘cross-clamp test’ to be performed, which if 
failed, allowed the placement of a temporary carotid shunt similar to standard 
carotid endarterectomy practice under local anaesthetic (26, 27).  
 
Huczek et al. were the only study to use transcranial Doppler monitoring (TCD), 
an established method of judging cerebral embolic load during procedures, 
followed by postoperative diffusion-weighted MRI to look for silent neurological 
damage (6). They found 160 and 200 high intensity signals (HITS), equivalent to 
cerebral embolic load, in their two cases - mostly during prosthesis deployment. 
In their second case they discovered a silent ischaemic lesion in the right 
subcortical area of the front lobe. A recent study by Alassar and colleagues found 
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a mean cerebral load of 134 (range 76-244) in 85 TAVI (via mainly transfemoral 
route, but also subclavian and transaortic) (28). They also found 76% of cases 
had ischaemic lesions on DW-MRI at 6 days. This suggests that silent ischaemic 
lesions are commonplace in TAVI procedures and the cerebral load seen in 
carotid access procedures appears comparable.  
 
 
4.3 Vascular access site complications 
There was one incidence of intraoperative dissection of the aorta and left carotid 
artery on insertion of the guide wire, in the first case report (10). This did not 
require abortion of the procedure and was shown to be completely resolved 
following the procedure with the patient having a good final outcome. In 
transfemoral access TAVI aortic dissection is reported in up to 2% of patients, 
while rates of iliofemoral dissection can be as high as 7.4% when a surgical 
cutdown is used and 21.4% with percutaneous closure (29).  
 
There was one incidence of a vascular access site complication - a femoral 
haematoma from insertion of the pacing wire (8). Importantly there were no 
vascular access site complications at the carotid. This is promising and appears 
comparable with incidence rates of 2 to 18% in large series studies on 
transfemoral TAVI (29).  Furthermore there were no cases of access site 
infection, seen in up to 6.3% of transfemoral access cases (29), and this is 
reflective of infection rates following carotid endarterectomy which are less than 
1% (30).  
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4.4 TAVI-related complications and outcomes 
Specific TAVI-related complications and outcomes are well reported in the 
literature for transfemoral access (31) and a secondary consideration of this 
review is whether carotid access has a negative impact on these.  
 
Rates of pacemaker insertion (12.2%), myocardial infarction (0 patients), acute 
kidney injury requiring new dialysis (1 patient), need for transfusion (10 
patients) found in this review were all comparable to those seen in a study of 
270 patients undergoing TAVI via a transfemoral route (32).  
 
The rate of moderate or severe paravalvular regurgitation was 4.1%. Thourani 
and colleagues found comparable rates of moderate or severe paravalvular 
regurgitation in 2.2% of patients undergoing TAVI via a transapical route and 
2.9% via a transaortic route (19). 4.1% also compares favourably with a 
moderate or severe paravalvular regurgitation rate of 11.8% seen in the 
PARTNER trial in patients undergoing TAVI via transfemoral access (33).  
 
The six studies that reported transvalvular mean pressure gradient pre- and 
post-procedure all showed a satisfactory improvement in valve function (8, 15, 
17-20). Similarly, all studies that reported outcome at follow-up stated an 
improvement in NYHA classification or other symptomatic improvement.  
 
These findings suggest that there is no negative impact on valve placement via 
the carotid access route. This is further supported by qualitative reports that 
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carotid access provides a more accurate sheath delivery and stability, better 
movement precision, more direct access and a more accurate prosthesis 
positioning (13, 15, 20, 34).  
 
 
4.5 Surgical technique and equipment 
There is currently no consensus as to which carotid side is preferred. Some 
studies championed the left carotid as it offered a more direct approach (8, 18, 
24), others the right carotid due to favourable angulation (13, 23) and finally 
some sides were selected based on individual patient anatomy established on 
pre-operative imaging (14, 15, 22). This case-by-case decision-making based on 
the individual anatomy and surgeon preference seems to be the most sensible 
method at this time given the paucity of data.   
 
 
General anaesthesia carries well-known risks in elderly and frail patients, and 
this is often the same patient population that require TAVI as they are unfit for 
open surgery. Research has shown local anaesthetic to be safe and efficient for 
internal carotid endarterectomy (26). Gurer and colleagues showed that it  
reduced operation time, shunt usage, hospitalisation time and permanent stroke 
rates in this procedure (27). 23 patients underwent TAVI via carotid access 
under local anaesthetic in this systematic review. The feasibility of carotid access 
via local anaesthetic increases its appeal as, unlike the other ‘alternative’ access 
routes, it does not automatically preclude those patients unfit for general 
anaesthetic. 
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4.6 Limitations of evidence 
There are four key limitations to the data presented. Firstly the current evidence 
available is composed of case reports, case series and cohort studies only, with 
no randomized control trials to date. Secondly the total sample size of 72 
patients is small. Thirdly the follow-up is heterogeneous across the studies with 
some not reported, some reviewed at 30-days and some followed-up for one 
year with no data beyond that timeframe. Finally the possibility of positive 
reporting or publication bias cannot be excluded which may have resulted in 
cases with poor outcomes not being reported in the literature.  
 
 
4.7 Implications for practice 
Accepting the limitations of the data discussed this systematic review suggests 
that carotid access provides a safe and feasible alternative access route for TAVI. 
Mortality, neurological complications and vascular access complications are 
comparable to the currently accepted access routes. While TAVI-related 
outcomes such as pacemaker insertion, general complications and 
echocardiographic outcomes are also non-inferior based on these data.  
 
Carotid access will offer an alternative access route to a subset of patients who, 
due to co-morbidities, are currently ineligible for other procedures and this is 
worth further exploration. 
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4.8 Implications for research 
Given the safety and feasibility of this access technique further research in the 
area is required. This should chiefly set out to address the limitations of the 
current data set, as described above. Future studies should be randomised 
controlled studies with a larger patient sample and follow-up at 30 days and 1 
year. They should clearly report the valve characteristics pre- and post- 
procedure, and again at 1 year follow-up. All complications should be reported 
according to the VARC-2 guidelines (12). These changes will give a more 
complete dataset and will give a more robust evidence base to support carotid 
access as an alternative route for the TAVI procedure.   
 
5. Conclusion 
Transcatheter aortic valve implantation (TAVI) via carotid access should be 
considered a safe and feasible alternative when transfemoral access is not 
available. This systematic review shows promising results for mortality, 
neurological complications and vascular access complications from data on 72 
patients. Furthermore there is no obvious negative impact in terms of results 
from valve implantation. This creates an opportunity for a subset of patients to 
have a valve replacement that may not previously have been possible.  
 
Further research, ideally in the form of randomised controlled trials, should seek 
to support these findings and answer whether this technique should become the 
first alternative to transfemoral access or even the primary TAVI access route. 
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